• Webcast cover image - CAR T cell engagement

    In this webcast our speakers Dr. Marcela Maus and Dr. jos Melenhorst will discuss pre-clinical and clinical progress in CAR T cell therapy and highlight limitations and challenges. The presentations are followed by a discussion moderated by Dr. Lisa Haas (Associate Editor, Nature Cancer). Registration is free! June 30th, 8 am PDT | 11am EDT | 4pm BST | 5pm CEST

  • We are looking for a new editor to join the Nature Cancer editorial team in our New York, Washington DC and Philadelphia offices in the US; London, Berlin, Madrid and Milan in Europe; and Shanghai in Asia. Application deadline July 17th.

  • Nature Cancer pictorial

    View webcasts hosted by Nature Cancer editors, in which expert cancer researchers and clinicians discuss the most exciting advances and biggest challenges in their fields. Past events can be accessed on demand for free by registering your attendee details.

  • Nature Cancer Series Cover - image of medications in ingestible and injectable form.

    Nature Cancer presents a Series of commissioned Review and Perspective articles highlighting emerging concepts in cancer therapy, novel therapeutic approaches and the challenges in translating preclinical findings into clinical benefit, accompanied by a collection of relevant primary research and News and Comment articles published by Nature Cancer.

Nature Cancer is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


    • Therapy resistance limits the clinical success of tyrosine kinase inhibitors (TKIs) in ALK-positive non-small cell lung cancer. A study now proposes a framework to identify compound resistance mutations to the lorlatinib TKI and provides structure-based drug design approaches to overcome resistance mediated by ALK(G1202R) or ALK(I1171N/S/T).

      • Liu He
      • Arvin C. Dar
      News & Views
    • The lethality of prostate cancer is driven by its progression to a castration-resistant state. A new study identifies gremlin 1 (GREM1) as an agonist of fibroblast growth factor receptor 1 (FGFR1) that drives such progression when androgen receptor (AR) signaling is low, nominating GREM1 as a therapeutic target for prostate cancer with low AR activity.

      • Laura A. Sena
      • W. Nathaniel Brennen
      • John T. Isaacs
      News & Views
    • Acute myeloid leukemia (AML) is characterized by distinct genetic and molecular alterations, including rearrangements in the mixed lineage leukemia (MLL) gene. A study now presents a therapeutic strategy for MLL-rearranged (MLL-r) AML that exploits a unique co-dependency on IKAROS and MENIN.

      • LaQuita M. Jones
      • Daniel T. Starczynowski
      News & Views
    • Patients with cancer are known to be at increased risk of infection and severe complications from COVID-19, with vaccination being key for their protection. A prospective study now evaluates the effect of vaccination against COVID-19 on the immune response mounted by patients with lymphoma.

      • Ariel Fromowitz
      • Amit Verma
      News & Views
  • As guidelines, therapies and literature on cancer variants expand, the lack of consensus variant interpretations impedes clinical applications. CIViC is a public-domain, crowd-sourced and adaptable knowledgebase of evidence for the clinical interpretation of variants in cancer, designed to reduce barriers to knowledge sharing and alleviate the variant-interpretation bottleneck.

    • Kilannin Krysiak
    • Arpad M. Danos
    • Malachi Griffith
  • Nature Cancer and the Nature journals are raising the standards on reporting on sex and gender in research. Starting this June, authors will be prompted to provide details on how sex and gender were considered in study design.

  • The advent of EGFR inhibitors has been a game changer in clinical oncology. However, differing sensitivity to different mutations, resistance and adverse effects continue to impede decisive treatment of mutant EGFR–driven cancers, which highlights the need for advanced and innovative EGFR-targeting approaches.

  • A deeper understanding of the specific tumor context and microenvironment, the underlying tumor immunology, and barriers to effective treatment, including therapy resistance and adverse effects, is essential to the development of improved immunotherapy modalities and regimens.

  • A deeper understanding of the molecular and cellular underpinnings of metastatic disease and a renewed focus on metastasis-targeting therapeutic approaches raise hopes for improved clinical translation.

Image of different types of therapies, including pills and injectables, taken from the March 2021 issue cover of Nature Cancer.

Series on Cancer Therapy

Cancer therapy has advanced significantly in recent years, however, cancer remains a major health problem that requires further discovery and innovation to improve outcomes and quality of life for patients.